• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
BEZ235

BEZ235

Product ID B1996
Cas No. 915019-65-7
Purity ≥98%
Product Unit SizeCostQuantityStock
10 mg $63.60 In stock
25 mg $136.70 In stock
100 mg $410.20 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

BEZ235 inhibits PI3K and mTORC1/2, exhibiting anticancer chemotherapeutic activity. In nasopharyngeal cancer cells, BEZ235 induces G1 phase cell cycle arrest and apoptosis; in similar animal models of nasopharyngeal or cholangiocarcinoma, this compound inhibits tumor growth. BEZ235 also induces apoptosis in hepatocellular carcinoma cells, also potentially inducing autophagy.

Product Info

Cas No.

915019-65-7

Purity

≥98%

Formula

C30H23N5O

Formula Wt.

469.54

IUPAC Name

2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile

Synonym

NVP-BEZ235, Dactolisib

Solubility

DMF 18 mg/mL warmed (38.33 mM) DMSO 0.01 mg/mL (0.02 mM) Water Insoluble

Appearance

White Crystal Powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

B1996 MSDS PDF

Info Sheet

B1996 Info Sheet PDF

Brochures

PI3K-Akt-mTORC Pathway Booklet

References

Ma BB, Lui VW, Hui CW, et al. Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. Cancer Lett. 2014 Feb 1;343(1):24-32. PMID: 24041865.

Yothaisong S, Dokduang H, Techasen A, et al. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Tumour Biol. 2013 Dec;34(6):3637-48. PMID: 23832540.

Chang Z, Shi G, Jin J, et al. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy. Int J Mol Med. 2013 Jun;31(6):1449-56. PMID: 23588698.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • C294458

    Chlorzoxazone

    Centrally acting muscle relaxant.

    ≥99%
  • S8007

    Substance P (1-7)

    Endogenous tachykinin peptide, involved in infl...

    ≥95%
  • M1779

    Methyldopa Sesquihydrate

    DOPA decarboxylase inhibitor, indirect α2-adre...

    ≥98%
  • F6803

    FRAX486

    PAK inhibitor.Smo inhibitor.

    ≥98%
  • R2815

    Recombinant HIV-1 “0” group consensus

    Recombinant HIV-1 antigen fragment.

    ≥95%
  • W7200

    WS3

    Islet β cell proliferation stimulator.

    ≥98%
  • A5037

    Amiodarone Hydrochloride

    Voltage-gated Na+, Ca2+, K+ channel blocker, α...

    ≥98%
  • P0001

    P1 Peptide

    Octapeptide, prevents EGFR-PLCγ association.

    ≥95%
  • I0800

    IC-87114

    p110δ PI3K inhibitor.

    ≥98%
  • P327211

    Pifithrin-α Hydrobromide

    p53 inhibitor

    ≥98%
  • C3214

    CID-797718

    Potential PKD binding agent.

    ≥99%
  • B349921

    BIX-01294

    Specific inhibitor of histone methyltransferase...

    ≥99%
  • M1685

    Mevastatin

    Statin; HMG-CoA reductase inhibitor.

    ≥98%
  • S584780

    Sotorasib racemate

    KRAS inhibitor

    ≥99%
  • Z4552

    ZLN005

    PPARγ coactivator-1α expression stimulator.

    ≥98%
  • R5974

    Rosuvastatin Calcium

    Statin; HMG-CoA reductase inhibitor, potential ...

    ≥98%
  • C6019

    C-Peptide, human

    Endogenous peptide, connects A and B chains of ...

    ≥95%
  • R3476

    RITA

    p53 activator.

    ≥98%
  • A4777

    Altiratinib

    c-MET, Tie-2, VEGFR inhibitor.

    ≥98%
  • L589938

    LOXO-195

    Inhibitor of TRK.

    ≥99%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only